Mechanism of action
Selectively and reversibly inhibits thrombin (factor IIa), preventing fibrin clot formation and thrombin-mediated platelet aggregation. Rapid onset and reversible binding provide predictable pharmacokinetics.
Oral direct thrombin (factor IIa) inhibitor for stroke prevention in AF and VTE treatment. RE-LY trial showed superiority to warfarin in stroke prevention and significantly lower intracranial hemorrhage.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.